Import Bottlenecks Continue Burdening Sri Lanka’s Pharmaceutical Manufacturing Sector
Sri Lanka’s pharmaceutical manufacturers are urging authorities to simplify regulatory procedures governing imported raw materials, warning that lengthy approval processes continue to increase costs, delay production and weaken the competitiveness of local medicine manufacturers.
Industry leaders argue that while finished pharmaceutical imports often enter the country through comparatively streamlined procedures, local manufacturers producing medicines domestically must obtain multiple approvals for every shipment of pharmaceutical ingredients.
According to Sri Lanka Pharmaceutical Manufacturers’ Association President Dinesh Athapaththu, these regulatory requirements create operational delays that ultimately affect manufacturing efficiency and investment decisions.
Speaking after assuming office at the Association’s 60th Annual General Meeting, Athapaththu said regulatory reforms could significantly strengthen the industry’s ability to compete both locally and internationally.
Manufacturers contend that pharmaceutical production depends on uninterrupted access to high-quality raw materials sourced from overseas suppliers. Delays in customs clearance or multiple regulatory approvals can disrupt production schedules, increase inventory costs and create uncertainty throughout the manufacturing process.
Industry representatives are therefore calling for closer consultation between regulators and manufacturers to identify opportunities for simplifying import procedures without compromising quality or patient safety.
The sector maintains that improved regulatory efficiency would allow companies to respond more quickly to market demand while lowering operating costs.
Beyond regulatory issues, manufacturers also stress that pharmaceutical production requires exceptionally high capital investment and extended development periods. Companies must construct sophisticated manufacturing facilities, validate production systems, obtain regulatory approvals and establish market acceptance before recovering their investments.
These long investment cycles mean manufacturers are particularly sensitive to policy changes that could affect commercial viability.
The industry’s concerns extend beyond business performance to national healthcare resilience.
The COVID-19 pandemic exposed vulnerabilities in global pharmaceutical supply chains as many countries experienced shortages of essential medicines. Those disruptions renewed attention on the importance of maintaining domestic manufacturing capacity capable of supporting national healthcare requirements during emergencies.
Industry leaders believe Sri Lanka can reduce dependence on imported medicines by creating a more supportive regulatory environment that encourages domestic production while maintaining international quality standards.
They argue that simplifying raw material import procedures represents one practical reform that could immediately improve productivity without requiring significant public expenditure.
Combined with stable procurement policies and continued investment incentives, regulatory reforms could help position Sri Lanka’s pharmaceutical manufacturing industry for sustained expansion while strengthening the country’s long-term pharmaceutical security.
As policymakers continue to explore strategies for industrial development and healthcare resilience, manufacturers maintain that reducing administrative bottlenecks may prove just as important as financial incentives in creating an environment capable of attracting long-term investment and expanding local medicine production.
The post Import Bottlenecks Continue Burdening Sri Lanka’s Pharmaceutical Manufacturing Sector appeared first on LNW Lanka News Web.
